1. Home
  2. NGNE vs NATH Comparison

NGNE vs NATH Comparison

Compare NGNE & NATH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$35.40

Market Cap

498.2M

Sector

Health Care

ML Signal

HOLD

Logo Nathan's Famous Inc.

NATH

Nathan's Famous Inc.

HOLD

Current Price

$101.42

Market Cap

418.8M

ML Signal

HOLD

Company Overview

Basic Information
Metric
NGNE
NATH
Founded
2003
1916
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
498.2M
418.8M
IPO Year
2014
1996

Fundamental Metrics

Financial Performance
Metric
NGNE
NATH
Price
$35.40
$101.42
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
219.9K
20.3K
Earning Date
05-08-2026
06-09-2026
Dividend Yield
N/A
1.99%
EPS Growth
0.93
N/A
EPS
N/A
4.85
Revenue
N/A
$104,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$20.91
Revenue Growth
N/A
7.81
52 Week Low
$15.93
$88.67
52 Week High
$37.27
$117.49

Technical Indicators

Market Signals
Indicator
NGNE
NATH
Relative Strength Index (RSI) 68.81 51.38
Support Level $19.27 $100.32
Resistance Level $36.37 $101.76
Average True Range (ATR) 2.05 0.63
MACD 0.39 -0.02
Stochastic Oscillator 95.22 60.98

Price Performance

Historical Comparison
NGNE
NATH

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About NATH Nathan's Famous Inc.

Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.

Share on Social Networks: